Phase 3
Completed N=744
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Source: ClinicalTrials.gov NCT03073486 ↗Enrolled (actual)
744
Serious AEs
0.1%
Results posted
Feb 2019
Primary outcomePrimary: Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 — -17.0; -15.4 Lesions — p=0.2301
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 |
-17.0; -15.4 | 0.2301 |
| PRIMARY Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 |
-18.0; -17.6 | 0.6888 |
| PRIMARY Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 |
80; 30; 413; 221 | 0.1361 |
Eligibility Criteria
Inclusion Criteria
- Signed informed consent and, for subjects under legal adult age, signed assent
- Age ≥ 9 years
- Clinical diagnosis of facial acne vulgaris defined as:
- At least 20 inflammatory lesions, and
- At least 20 non-inflammatory lesions, and
- Investigator Global Assessment of 3 or greater
Exclusion Criteria
- Active cystic acne or acne conglobata, acne fulminans, and secondary acne
- Two or more active nodulocystic lesions on the face
- Clinically significant abnormal laboratory or ECG result
- Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days or 5 half-lives (whichever is longer) of the Baseline visit
- Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to Baseline
- Treatment with systemic antibiotics or systemic anti-acne drugs or topical retinoid within 4 weeks prior to Baseline
- Treatment with a new hormonal therapy or dose change to existing hormonal therapy within 12 weeks prior to Baseline (hormonal therapies include, but are not limited to, estrogenic and progestational agents such as birth control pills).
- Use of androgen receptor blockers (such as spironolactone or flutamide) within 2 weeks prior to Baseline.
- Oral retinoid use (e.g., isotretinoin) within 12 months prior to Baseline or vitamin A supplements greater than 10,000 units/day within 6 months prior to Baseline
- Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8 weeks
Data sourced from ClinicalTrials.gov (NCT03073486). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.